openPR Logo
Press release

Oncolytic Virus Therapy Clinical Trials FDA Approval Market Size Forecast

10-04-2024 08:33 AM CET | Health & Medicine

Press release from: KuicK Research

Oncolytic Virus Therapy Clinical Trials FDA Approval Market

Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights:

• Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion By 2030
• Oncolytic Viruses Immunotherapies Clinical Trials By Company, Indication & Phase
• Comprehensive Insight On Oncolytic Virus Immunotherapies In Clinical Trials: > 180 Therapies
• FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME
• Patent Analysis Therapies in Clinical Trials
• IMLYGIC, Oncorine, Delytact: Availability, Dosage and Price Analysis
• Platforms Used For Developing Advanced Oncolytic Virus Immunotherapy

Download Report:

https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas

In the preceding decennium, one of the outmost noteworthy discoveries that took place in the field of cancer treatment is the fact that tumors can develop an innovative strength "field-like defense" against the immune system. This has led to an upsurge in the domain by several novel researches and investigations with the intention of finding a novel approach which will aid to breakdown the tumor defense. To further progress cancer treatment, healthcare professionals discovered that by taking benefit of a virus that can enter the cell and then precisely infect the cancerous cells can be used to develop a novel therapeutic approach. This finding led to the advent of oncolytic virus immunotherapy as a ground breaking approach to multitudinous patients suffering from cancer by providing a safer, practical and effective treatment option.

In dichotomy with the conventional therapies, such as chemotherapy, radiotherapy, or targeted immunotherapies, although being effective, it comes together with Achilles heels like progression of drug resistances, thereby reducing the ability to address the advanced stages of the cancer malignancies. Therefore, in order to tackle these limitations the field of oncolytic virus immunotherapy exemplifies a pioneering paradigm in the sphere of cancer treatment, cementing the precision of virology along with leveraging the power of immune system to combat malignancies. At its core, this innovative therapeutic approach involves the genetic modifications of viruses to enhance their tumor targeting capabilities while sparing normal, healthy cells.

By simultaneously targeting the pathways or antigens crucial to cancer growth and survival, the realm of oncolytic virus immunotherapy seeks to enhance treatment efficacy and address issues such as drug resistance that come along with usage of conventional therapies. This approach clenches the potential to revolutionize cancer care by offering a more nuanced and adaptive treatment strategy, aiming not only to kill cancer cells directly but also to modulate the immune system for a sustained and potent anti- cancer response.

The chronicle of oncolytic virus immunotherapy is rooted in the late 1950s to 1970s in which multiple clinical trials and studies were ongoing with wild type viruses in order to understand the mode of action to treat tumor cells. Moreover, oncolytic viral therapy provides enormous advantage such as higher response towards cancer cells owing to the presence of impaired antiviral defense in addition to better delivery of therapeutic payloads to tumor cells as compared to the conventional treatment which aims to reduce or delays the symptoms of cancer.

The commercial market for oncolytic virus immunotherapy gained significant momentum with the approval of Oncorine (H101) in 2005 by the China National Medical Product Administration (NMPA) for the treatment of head and neck cancer. Developed by Shanghai Sunway Biotech Pharma, Oncorine is a recombinant human adenovirus type 5 that has been genetically modified with deletions in the e1b-55kd and e3 regions. This innovative therapy offers distinct advantages over conventional treatments like cisplatin and carboplatin, including enhanced efficacy and direct tumor lysis, while minimizing the dose-limiting side effects and drug resistance often associated with traditional chemotherapy.

The introduction of Oncorine as a pioneering oncolytic virus immunotherapy heralded a new era in cancer treatment, promising a novel therapeutic strategy. This breakthrough inspired a surge of research and development, leading to the approval of two additional innovative viral therapies: Imlygic (talimogene laherparepvec), developed by Amgen in 2015 for the treatment of metastatic melanoma, and Delytact (Teserpaturev/G47Δ), developed by Daiichi Sankyo in collaboration with the University of Tokyo's Institute of Medical Science in 2021 for malignant glioma. These advancements underscore the growing potential of oncolytic virus therapies in the fight against cancer.

In conclusion, the field of oncolytic virus immunotherapy emerges as a revolutionary frontier in the battle against cancer cells. Advantages such as providing a tailored and multifaceted approach to address cancer, the precision in direct tumor lysis, coupled with the ability to stimulate a potent immune response, compromises a ray of anticipation for patients facing the complexities of this malignancy. As the research further endure to fill the gap that is created by the conventional therapies, oncolytic virus therapy stands out as a beacon of innovation, clenching promise not only for localized disease control but also for impeding progression of cancer malignancies. The tailored and targeted approach aligned with principles of personalized medicine, heralds a new epoch in which patients and clinicians can envision a more effective, resilient along with individualized strategy to control the augmenting gait of cancer.

KuicK Research
Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oncolytic Virus Therapy Clinical Trials FDA Approval Market Size Forecast here

News-ID: 3677711 • Views:

More Releases from KuicK Research

PROTAC Cancer Therapy PROTAC Drugs Clinical Trials Insight
PROTAC Cancer Therapy PROTAC Drugs Clinical Trials Insight
Global Proteolysis Targeting Chimeras PROTAC Therapy Clinical Trials Insight & Market Opportunity Report Highlights: • First PROTAC Drug Approval Expected By 2027 • Insight On More Than 50 PROTAC Drugs In Clinical Trials • Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase • Orphan & Fast Track Designation Insight • PROTAC Drugs Clinical Application & Development Outlook By Indication • Current & Future Market Overview • Global PROTAC Drug Market Dynamics Download Report: https://www.kuickresearch.com/ccformF.php?t=1728551968 PROTACs, or proteolysis-targeting chimeras, have emerged as a
Brazil Clinical Trials Market ANVISA Brazil Guidelines Brazil Clinical Trials Registry insight
Brazil Clinical Trials Market ANVISA Brazil Guidelines Brazil Clinical Trials Re …
Brazil Cancer Drugs Clinical Trials Insight 2024 Report Offering: • Brazil Clinical Trials Market Opportunity 2024 and 2030 (In US$ Billion) • Clinical Trials Regulatory Framework In Brazil • Total Number of Cancer Drugs In Clinical Trials In Brazil • Total Number Of Cancer Drugs Approved In Brazil • 400 Pages Clinical Trials Insight On All Cancer Drugs In Clinical Trials By Company, Indication and Phase • 80 Pages Clinical Insight On All Cancer Drugs Approved in Market By Company and Indication • Insight
VISTA inhibitors Drugs Clinical Trials FDA Approval Market Opportunity Insight
VISTA inhibitors Drugs Clinical Trials FDA Approval Market Opportunity Insight
Global VISTA Inhibitor Clinical Trials and Market Opportunity Insight 2024 Report Highlights: • Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase • VISTA Inhibitors Clinical Trials: 8 Drugs • US Dominating VISTA Inhibitors Clinical Trials Landscape: 5 Drugs • Global VISTA Inhibitors Market Trends and Clinical Innovation • Competitive Landscape: Insight On 10 Companies • Future Clinical and Commercialization Opportunities Download Report: https://www.kuickresearch.com/report-visti-inhibitors-clinical-trials-vista-inhibitors-antibody-vista-checkpoint-inhibition-vista-inhibitors-cancer-immunotherapy--vista-expression The field of immunotherapy in the fight against cancer has long been regarded as an essential
Trispecific Antibody Market Opportunity Outlook
Trispecific Antibody Market Opportunity Outlook
Global Trispecific Antibodies Clinical Trials and Market Outlook 2024 Report Highlights: • Trispecific Antibodies In Clinical Trials: > 50 Antibodies • Majority Of Antibodies Developed For Multiple Myeloma: 8 Antibodies • Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase • Platforms Used For Pioneering Trispecific Antibody • China Dominating Trispecific Antibodies Clinical Trials: >20 Antibodies • Competitive Landscape: Insight On 18 Companies Download Report: https://www.kuickresearch.com/report-trispecific-antibodies-market-trispecific-antibody-clinical-trials-fda-approved-trispecific-antibodies Cancer withstands to be a persistent adversary, challenging both patients and the medical community across the globe.

All 5 Releases


More Releases for Oncolytic

Oncolytic Virus Market: Know Applications Supporting Impressive Growth
A new business intelligence report released by HTF MI with title "Global Oncolytic Virus Market Professional Survey Report 2019" is designed covering micro level of analysis by manufacturers and key business segments. The Global Oncolytic Virus Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Oncolytic Virus 1.1 Outline of Oncolytic Virotherapy 1.2 Trail from Genesis to Biogenetics Primer of Virotherapy in Malignancies 2.1 Oncolytic Viruses towards Cancer 2.2 Approaches for Targeting Tumor Cells 2.2.1 Pro Apoptotic Targeting 2.2.2 Translational Targeting 2.2.3 Transcriptional Targeting 2.2.4 Transductional Targeting Mechanism
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic
Global Oncolytic Virus Therapy Market & Oncolytic Virus clinical Trials Outlook …
Advancements in human genomics over the last two decades have shown that cancer is mediated by somatic aberration in the host genome. This discovery has incited enthusiasm among cancer researchers; many now use therapeutic approaches in genetic manipulation to improve cancer regression and find a potential cure for the disease. The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low
Global Oncolytic Virus Therapy Pipeline Analysis
Though still in nascent stages, Oncolytic viruses have shown immense opportunities and potential to be tapped in the future to improve the treatment of cancer and the lives of the patients. Immunotherapy, the umbrella for Oncolytic viruses would not offer cures, but survival solutions with significant importance. Also, the side effects of this therapy would be tolerable by the patients, which could thus become the most important approach to treat
Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic